Drug intelligence / Profile preview

4-(acetylamino)-3-guanidinobenzoic acid

Development stage
Unknown
Lead developer
BioCryst Pharmaceuticals
Modality
Small Molecules
01

Overview

**4-(Acetylamino)-3-Guanidinobenzoic Acid** is a synthetic small molecule compound with the chemical formula C10H14N4O3 and a molecular weight of approximately 238.24 g/mol[1][2][6]. It features a benzoic acid backbone substituted with an acetylamino group at the para (4-) position and a guanidino group at the meta (3-) position[2][6]. The compound has been investigated as an experimental agent, notably in structure-based drug design efforts targeting influenza neuraminidase, suggesting potential antiviral activity through inhibition of this viral enzyme[7]. However, it has not been approved for any clinical use or indication to date and remains primarily of research interest.

Other names
4-(Acetylamino)-3-Guanidinobenzoic Acid3-((diaminomethyl)amino)-4-acetamidobenzoic acid3-[(diaminomethyl)amino]-4-acetamidobenzoic acid4-acetamido-3-(diaminomethylideneamino)benzoic acid4-acetamido-3-(diaminomethylamino)benzoic acid
02

Targets

Neuraminidase

Beyond the preview

Go deeper on 4-(acetylamino)-3-guanidinobenzoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-(acetylamino)-3-guanidinobenzoic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call